Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:01 PM
Ignite Modification Date:
2025-12-24 @ 5:01 PM
NCT ID:
NCT00813150
Eligibility Criteria:
Inclusion Criteria:
* Previously diagnosed with multiple myeloma
* Primary refractory multiple myeloma or relapsed following 1 to 3 previous lines of therapy
* Karnofsky performance status must be equal to 60 percentage (ie, better or equal performance than requiring some help and taking care of most personal requirements)
* Has life expectancy estimated at screening must be of at least 6 months
* Agrees to protocol-defined use of effective contraception
Exclusion Criteria:
* Not received more than three previous lines of therapy for multiple myeloma
* Not received nitrosoureas or any other chemotherapy or immunotherapy or antibody therapy for multiple myeloma within 6 to 8 weeks before enrolment. Plasmapheresis must not be applied within 2 weeks before enrolment
* Patients with peripheral neuropathy or neuropathic pain of Grade 2 or greater intensity
* Patients with poorly controlled cardio vascular, vascular, pulmonary, gastro-intestinal, endocrine, neurological, psychiatric, hepatic, renal or metabolic diseases or hematological disorders
* Not have oligosecretory or non-secretory multiple myeloma
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00813150
Study Brief:
Protocol Section:
NCT00813150